Turning a blind eye to deferasirox's toxicity?

@article{Kontoghiorghes2013TurningAB,
  title={Turning a blind eye to deferasirox's toxicity?},
  author={GJ Kontoghiorghes},
  journal={The Lancet},
  year={2013},
  volume={381},
  pages={1183-1184}
}
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
TLDR
The design of tailored made personalised protocols using deferiprone and selected combinations with deferoxamine should be considered as optimum chelation therapies for the complete treatment and the prevention of iron overload in thalassaemia.
Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells
TLDR
The concept that monitoring kidney tissue iron depletion may decrease the risk of deferasirox nephrotoxicity is supported, suggesting a role for BclxL downregulation in iron depletion-induced cell death.
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East, and the Mediterranean, exceeds 100,000 live births per year. There are many genetic variants in thalassemia
New developments and controversies in iron metabolism and iron chelation therapy.
TLDR
New mechanisms of iron deposition, removal, distribution and toxicity have been identified using new techniques such as magnetic resonance imaging increasing the understanding of iron metabolic processes and the targeted treatment of related diseases.
THERAPEUTIC ADVANCEMENTS IN MANAGEMENT OF IRON OVERLOAD-A REVIEW Review Article
TLDR
This review focuses on the developments taking place in the field of iron overload treatment to find the most novel, efficient and safest iron decorporating agent.
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
TLDR
The short-term safety of deferasirox seems to be acceptable, however, follow up in the available studies was too short to assess long-term side effects, and only limited evidence is available assessing the efficacy regarding patient-important outcomes.
Deferasirox nephrotoxicity—the knowns and unknowns
TLDR
Observational studies are required to track current trends in deferasirox prescription, assess the epidemiology of defer asirox nephrotoxicity in routine clinical practice, explore the effect on outcomes of various monitoring and dose-adjustment protocols and elucidate the long-term consequences of the different features of neph rotoxicity.
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.
TLDR
The criteria for drug development, price levels and use needs to be readdressed to improve drug safety and minimise costs and new global health policies based on cheaper drugs can help the treatment of many categories of orphan and rare diseases and millions of orphan patients in developing countries.
Deferasirox's toxicity
...
1
2
...

References

SHOWING 1-3 OF 3 REFERENCES
Deferasirox nephrotoxicity—the knowns and unknowns
TLDR
Observational studies are required to track current trends in deferasirox prescription, assess the epidemiology of defer asirox nephrotoxicity in routine clinical practice, explore the effect on outcomes of various monitoring and dose-adjustment protocols and elucidate the long-term consequences of the different features of neph rotoxicity.
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.
TLDR
The criteria for drug development, price levels and use needs to be readdressed to improve drug safety and minimise costs and new global health policies based on cheaper drugs can help the treatment of many categories of orphan and rare diseases and millions of orphan patients in developing countries.
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases
TLDR
Preliminary preclinical and clinical toxicity evidence suggest that deferoxamine and deferasirox can only be safely used for these non-iron loaded conditions for short-term treatments of a few weeks, whereas deferiprone can be used for longer term treatments of many months.